Strategies for the Synthesis of Mono- and Bis-Thionaphthoquinones

The subclass of compounds which have the nucleus 1,4-naphthoquinone is the most various of the class of quinones, which have a big quantity of substances and a number of which have helpful purposes starting from medicinal chemistry to software in supplies with particular properties. The introduction of one or two substituents with the sulfur heteroatom in the naphthoquinone nucleus generates merchandise containing alkyl and aryl teams that amplify sure organic properties in opposition to micro organism, viruses and fungi. The inexperienced, purple, and brown algae have been proven to have helpful therapeutic properties in the prevention and therapy of neurodegenerative illnesses: Parkinson, Alzheimer’s, and Multiple Sclerosis, and different persistent illnesses.

There are a number of strategies of getting ready these compounds, primarily from low molecular weight naphthoquinones with two electrophilic websites succesful of reacting with sulfides producing variety and new lessons of compounds, together with new sulfur heterocycles and sulfur heterocycles fused with naphthoquinones. These compounds have been proven to be bioactive in opposition to a number of organic targets. This overview will describe the strategies of their synthesis and, when relevant, their organic actions.

Edible marine algae are wealthy in bioactive compounds and are, subsequently, a supply of bioavailable proteins, lengthy chain polysaccharides that behave as low-calorie soluble fibers, metabolically needed minerals, nutritional vitamins, polyunsaturated fatty acids, and antioxidants. Marine algae have been used primarily as gelling brokers and thickeners (phycocolloids) in meals and pharmaceutical industries in the final century, however latest analysis has revealed their potential as a supply of helpful compounds for the pharmaceutical, medical, and beauty industries.  In this overview are listed and described the essential parts of an appropriate eating regimen for sufferers with these illnesses. In addition, compounds derived from macroalgae and their neurophysiological actions are described.

Antiviral and immunomodulatory exercise of curcumin: A case for prophylactic remedy for COVID-19

Coronavirus disease-19 (COVID-19), a devastating respiratory sickness brought on by SARS-associated coronavirus-2 (SARS-CoV-2), has already affected over 64 million folks and triggered 1.48 million deaths, simply 12 months from the first prognosis. COVID-19 sufferers develop critical issues, together with extreme pneumonia, acute respiratory misery syndrome (ARDS), and or multiorgan failure on account of exaggerated host immune response following an infection. Currently, medication that have been efficient in opposition to SARS-CoV are being repurposed for SARS-CoV-2. During this public well being emergency, meals nutraceuticals may very well be promising prophylactic therapeutics for COVID-19.

Curcumin, a bioactive compound in turmeric, exerts various pharmacological actions and is extensively utilized in meals and conventional medicines. This overview presents a number of strains of proof, which counsel curcumin as a promising prophylactic, therapeutic candidate for COVID-19. First, curcumin exerts antiviral exercise in opposition to many sorts of enveloped viruses, together with SARS-CoV-2, by a number of mechanisms: direct interplay with viral membrane proteins; disruption of the viral envelope; inhibition of viral proteases; induce host antiviral responses. Second, curcumin protects from deadly pneumonia and ARDS by way of focusing on NF-κB, inflammasome, IL-6 trans sign, and HMGB1 pathways.

Breast most cancers is the most frequent feminine most cancers and one of the main causes of most cancers demise in girls. There are many chemotherapy brokers accessible for the therapy of breast most cancers, however the present therapeutic choices haven’t fulfilled the desired outcomes particularly for the drug-resistant breast most cancers remedy. Thus, there may be an pressing must develop novel anti-breast most cancers brokers. Coumarin is ubiquitous in pure and artificial bioactive compounds, and coumarin derivatives are readily interacting with a range of enzymes and receptors in breast most cancers cells.

Moreover, the coumarin-based Irosustat as the first-generation steroid sulfatase inhibitor in breast most cancers is below scientific evaluations, revealing the potential of coumarin derivatives as novel anti-breast most cancers brokers. This overview goals to explain the latest growth of pure and artificial coumarin derivatives with anti-breast most cancers potential, protecting the articles printed from 2015 to 2020. Third, curcumin is protected and well-tolerated in each wholesome and diseased human topics. In conclusion, collected proof signifies that curcumin could also be a possible prophylactic therapeutic for COVID-19 in the clinic and public well being settings.

 Strategies for the Synthesis of Mono- and Bis-Thionaphthoquinones

Phytochemical screening, in vitro antioxidant and enzyme inhibitory proprieties and acute toxicity of extracts from the aerial elements of Ephedra nebrodensis, supply of bioactive compounds

 The goal of this examine was to judge the in vitro antioxidant and the enzyme inhibitory properties and to establish the bioactive compounds current in the extracts of Ephedra nebrodensis rising in Algeria. Total phenolic and flavonoids content material in these extracts have been quantified by Folin-Ciocalteu and aluminum chloride strategies. The antioxidant capability was assessed utilizing DPPH, ABTS, β-carotene/linoleic acid, CUPRAC and FRAP assays and in vitro cholinesterase exercise in opposition to acetylcholinesterase and butyrylcholinesterase have been evaluated. The chemical constituents of the extracts have been analyzed by high-performance liquid chromatography coupled to mass spectrometric detection and gasoline chromatography coupled to mass spectrometric detection. For the acute toxicity examine, extracts have been administered to mice at single dose of 2 g/kg and 5 g/kg by gavage.

LILRB4 / CD85k / ILT3 Recombinant Protein

11-320 0.1 mg
EUR 595.25
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB4 / CD85k / ILT3 Recombinant Protein

11-484 0.1 mg
EUR 595.25
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB4 / CD85k / ILT3 Recombinant Protein

11-491 0.1 mg
EUR 658.25
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Recombinant human LILRB4/CD85k/ILT3 Protein

RP01155 10 μg
EUR 230

Recombinant human LILRB4/CD85k/ILT3 Protein

RP01185 10 μg
EUR 193

Human CellExp? LILRB4 / CD85k / ILT3, Cynomolgus Recombinant

P1187-10
EUR 164

Human CellExp? LILRB4 / CD85k / ILT3, Cynomolgus Recombinant

P1187-50
EUR 544

Human CellExp? LILRB4 / CD85k / ILT3, Mouse Recombinant

P1188-10
EUR 164

Human CellExp? LILRB4 / CD85k / ILT3, Mouse Recombinant

P1188-50
EUR 588

Human CellExp? LILRB4 / CD85k / ILT3, Mouse Recombinant

P1200-10
EUR 185

Human CellExp? LILRB4 / CD85k / ILT3, Mouse Recombinant

P1200-50
EUR 729

Recombinant Mouse LILRB4/CD85k/ILT3 (C-6His)

CS97-10ug 10ug
EUR 156
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Recombinant Mouse LILRB4/CD85k/ILT3 (C-6His)

CS97-1mg 1mg
EUR 1877
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Recombinant Mouse LILRB4/CD85k/ILT3 (C-6His)

CS97-500ug 500ug
EUR 1328
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Recombinant Mouse LILRB4/CD85k/ILT3 (C-6His)

CS97-50ug 50ug
EUR 369
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit

RD-LILRB4-Hu-48Tests 48 Tests
EUR 500

Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit

RD-LILRB4-Hu-96Tests 96 Tests
EUR 692

Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit

DLR-LILRB4-Hu-48T 48T
EUR 498
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) in samples from tissue homogenates, cell lysates or other biological fluids.

Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit

DLR-LILRB4-Hu-96T 96T
EUR 647
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) in samples from tissue homogenates, cell lysates or other biological fluids.

Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit

RDR-LILRB4-Hu-48Tests 48 Tests
EUR 522

Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit

RDR-LILRB4-Hu-96Tests 96 Tests
EUR 724

LILRB4 Recombinant Protein (Human)

RP017800 100 ug Ask for price

Human Angiotensin I, pure (bioactive)

AT55-P-5 5 mg
EUR 529

Human Angiotensin II, pure (bioactive)

AT65-P-5 5 mg
EUR 286

Human Angiotensin III, pure (bioactive)

AT75-P-5 5 mg
EUR 286

LILRB4 Recombinant Protein

96-518 0.05 mg
EUR 626.75
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB4 Recombinant Protein

96-808 0.1 mg
EUR 710.75
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB4 Recombinant Protein

96-809 0.1 mg
EUR 710.75
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB4 Recombinant Protein

97-012 0.1 mg
EUR 710.75
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB4 Recombinant Protein

97-013 0.1 mg
EUR 710.75
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

DiscoveryProbe? Bioactive Compound Library

L1022-.1 100 uL/well(10 mM solution)
EUR 23389

DiscoveryProbe? Bioactive Compound Library

L1022-.25 250 uL/well(10 mM solution)
EUR 42042

DiscoveryProbe? Bioactive Compound Library

L1022-5 5 mg/well
EUR 54686

Cyclophilin-F Rat Recombinant Protein Bioactive

PROTP29117-1 Regular: 10ug
EUR 317
Description: Cyclophilin F Rat Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 200 amino acids (30-206 a.a) and having a molecular mass of 21.2Da. Cyclophilin F is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

LILRB4 Antibody

CSB-PA297929-
EUR 335
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IF;IF:1:100-1:500

LILRB4 Antibody

CSB-PA297929-100ul 100ul
EUR 316
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IF;IF:1:100-1:500

LILRB4 Antibody

1-CSB-PA006757
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: IF, ELISA;IF:1/200-1/1000.ELISA:1/20000

LILRB4 Antibody

1-CSB-PA850914ESR1HU
  • EUR 222.00
  • EUR 335.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:1000-1:5000

LILRB4 Antibody

1-CSB-PA850914ESR2HU
  • EUR 222.00
  • EUR 335.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200

LILRB4 Antibody

34759-100ul 100ul
EUR 252

LILRB4 Antibody

34759-50ul 50ul
EUR 187

LILRB4 siRNA

20-abx922563
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol

LILRB4 siRNA

20-abx922564
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol

anti-LILRB4

YF-PA25711 50 ul
EUR 334
Description: Mouse polyclonal to LILRB4

LILRB4 antibody

70R-35844 100 ug
EUR 327
Description: Rabbit polyclonal LILRB4 antibody

LILRB4 Recombinant Protein (Rat)

RP208181 100 ug Ask for price

LILRB4 Recombinant Protein (Mouse)

RP147467 100 ug Ask for price

Human LILRB4 shRNA Plasmid

20-abx957516
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg

Human LILRB4 ELISA KIT

ELI-45775h 96 Tests
EUR 824

LILRB4 ELISA KIT|Human

EF006382 96 Tests
EUR 689

Human LILRB4 ELISA Kit

ELA-E5609h 96 Tests
EUR 824

Human Angiotensin II (1-4), pure (bioactive)

AT66-P-5 5 mg
EUR 286

Human Angiotensin II (3-8), pure (bioactive)

AT67-P-5 5 mg
EUR 286

Human Angiotensin II (4-8), pure (bioactive)

AT68-P-5 5 mg
EUR 286

Human Angiotensin II (5-8), pure (bioactive)

AT69-P-5 5 mg
EUR 286

DCXR Human, Dicarbonyl/L-Xylulose Reductase Human Recombinant Protein, Bioactive

PROTQ7Z4W1-1 Regular: 10ug
EUR 317
Description: DCXR Recombinant Human produced in E.Coli is a single, non-glycosylated polypeptide chain containing 264 amino acids (1-244 a.a.) and having a molecular mass of 28 kDa. The DCXR is fused to a 20 amino acids His-Tag at N-terminus and purified by proprietary chromatographic techniques.

LILRB4 cloning plasmid

CSB-CL850914HU-10ug 10ug
EUR 233
Description: A cloning plasmid for the LILRB4 gene.

Anti-LILRB4 antibody

STJ29153 100 µl
EUR 277
Description: This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. The receptor can also function in antigen capture and presentation. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene.

LILRB4 Rabbit pAb

A7073-100ul 100 ul
EUR 308

LILRB4 Rabbit pAb

A7073-200ul 200 ul
EUR 459

LILRB4 Rabbit pAb

A7073-20ul 20 ul
EUR 183

LILRB4 Rabbit pAb

A7073-50ul 50 ul
EUR 223

LILRB4 Conjugated Antibody

C34759 100ul
EUR 397

pBluescriptR-LILRB4 Plasmid

PVT16920 2 ug
EUR 325

Rat/Canine Angiotensin I, pure (bioactive)

AT56-P-1 1 mg
EUR 286

LILRB4 ELISA Kit (Human) (OKEH01767)

OKEH01767 96 Wells
EUR 662
Description: Description of target: This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. The receptor can also function in antigen capture and presentation. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.082 ng/mL

LILRB4 ELISA Kit (Human) (OKCD07380)

OKCD07380 96 Wells
EUR 936
Description: Description of target: Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab);Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 0.057ng/mL

LILRB4 ORF Vector (Human) (pORF)

ORF005934 1.0 ug DNA
EUR 95

Human CellExp? LILRB4, Cynomolgus Recombinant

P1199-10
EUR 185

Human CellExp? LILRB4, Cynomolgus Recombinant

P1199-50
EUR 729

LILRB4 Protein Vector (Human) (pPB-C-His)

PV023733 500 ng
EUR 329

LILRB4 Protein Vector (Human) (pPB-N-His)

PV023734 500 ng
EUR 329

LILRB4 Protein Vector (Human) (pPM-C-HA)

PV023735 500 ng
EUR 329

LILRB4 Protein Vector (Human) (pPM-C-His)

PV023736 500 ng
EUR 329

LILRB4 Recombinant Protein (Human) (C-Fc Tag)

RP238855 1mg Ask for price

LILRB4 Recombinant Protein (Human) (C-Fc Tag)

RP238856 50ug Ask for price

Human Hepcidine-25 bioactive(Hepc-25) ELISA Kit

QY-E05472 96T
EUR 361

ENTPD3 Human, Ectonucleoside Triphosphate Diphosphohydrolase 3 Human Recombinant Protein, sf9 Bioactive

PROTO75355-2 Regular: 4ug
EUR 317
Description: ENTPD3 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 451 amino acids (44-485a.a.) and having a molecular mass of 50.7kDa (Molecular size on SDS-PAGE will appear at approximately 50-70kDa).;ENTPD3 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.

Mouse LILRB4 shRNA Plasmid

20-abx970615
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg

Anti-LILRB4/Gp49 Antibody

A04924 100ul
EUR 397
Description: Rabbit Polyclonal LILRB4/Gp49 Antibody. Validated in IF and tested in Human.

Mouse Lilrb4 ELISA KIT

ELI-42013m 96 Tests
EUR 865

Human LILRB4 Protein (Gln 22-Glu 259) [His]

VAng-1892Lsx-100g 100 µg
EUR 1013
Description: Human LILRB4 protein, His tag, expressed in human 293 cells. (Uniprot ID: AAH26309.1)

Human LILRB4 Protein (Gln 22-Glu 259) [His]

VAng-1892Lsx-1mg 1 mg
EUR 6402
Description: Human LILRB4 protein, His tag, expressed in human 293 cells. (Uniprot ID: AAH26309.1)

LILRB4 sgRNA CRISPR Lentivector set (Human)

K1215601 3 x 1.0 ug
EUR 339

IMPAD1 Inositol Monophosphatase Domain Containing 1 Mouse Recombinant Protein Bioactive

PROTQ80V26-1 Regular: 10ug
EUR 317
Description: IMPAD1 Mouse Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 332 amino acids (34-356a.a.) and having a molecular mass of 36.2kDa. (Molecular size on SDS-PAGE will appear at approximately 28-40kDa). IMPAD1 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.

LILRB4 Protein Vector (Rat) (pPB-C-His)

PV277578 500 ng
EUR 603

LILRB4 Protein Vector (Rat) (pPB-N-His)

PV277579 500 ng
EUR 603

LILRB4 Protein Vector (Rat) (pPM-C-HA)

PV277580 500 ng
EUR 603

LILRB4 Protein Vector (Rat) (pPM-C-His)

PV277581 500 ng
EUR 603

LILRB4 Protein Vector (Mouse) (pPB-C-His)

PV196626 500 ng
EUR 603

LILRB4 Protein Vector (Mouse) (pPB-N-His)

PV196627 500 ng
EUR 603

LILRB4 Protein Vector (Mouse) (pPM-C-HA)

PV196628 500 ng
EUR 603

LILRB4 Protein Vector (Mouse) (pPM-C-His)

PV196629 500 ng
EUR 603

LILRB4 ELISA Kit (Mouse) (OKEH05081)

OKEH05081 96 Wells
EUR 662
Description: Description of target: Receptor for class I MHC antigens. Involved in the down-regulation of the immune response and the development of tolerance. Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.177 ng/mL

Lilrb4 ORF Vector (Mouse) (pORF)

ORF049157 1.0 ug DNA
EUR 95

Lilrb4 ORF Vector (Rat) (pORF)

ORF069395 1.0 ug DNA
EUR 506

LILRB4 sgRNA CRISPR Lentivector (Human) (Target 1)

K1215602 1.0 ug DNA
EUR 154

LILRB4 sgRNA CRISPR Lentivector (Human) (Target 2)

K1215603 1.0 ug DNA
EUR 154
Plant extracts have been wealthy in phenolic compounds. Ethyl acetate extract introduced the highest phenolic (238.44 ± 1.50 µg GAE /mg of extract) and flavonoid (21.12 ± 0.00 µg QE /mg of extract) contents. Likewise, ethyl acetate extract confirmed potent radical scavenging and decreasing properties. Ethanol: acetone extract confirmed inhibitory exercise in opposition to acetylcholinesterase, and was a potent inhibitor of butyrylcholinesterase. In all extracts, flavonoids have been the most ample compounds. The phytochemical investigation confirmed the presence of alkaloids (ephedrine and pseudo-ephedrine). In the acute toxicity, the LD50 was superior to five g/kg physique weight. There are usually not alterations in the histology of the liver and kidneys.